|
Adenocarcinoma Of Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of <i>MAGEA6</i> in human esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) tissue samples were compared with those in paracancerous tissue.
|
31410142 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
|
12208877 |
2002 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MAGEA6 expression is correlated with AMPKα1 downregulation in RCC tissues and cells.
|
29448247 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma.
|
12631591 |
2003 |
|
Esophageal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study focused on the association of EC with the expression of MAGE family member A6 (MAGEA6) at the mRNA and protein levels using gene chip, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry.
|
31410142 |
2019 |
|
Familial multiple trichoepitheliomata
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
An higher positive rate of <i>MAGEA6</i> expression in ESCC and EAC tissues was also revealed when compared with paracancerous tissues, as determined via immunohistochemistry.
|
31410142 |
2019 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, MAGEA6 promotes glioma cell survival possibly via targeting AMPKα1.
|
29024810 |
2018 |
|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Afterwards, a rescue experiment was conducted and revealed that MAGEA6 silencing reversed the effects of miR-448 inhibitor on stemness maintenance and self-renewal of HCC stem cells.
|
31232474 |
2019 |
|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Database search confirmed that MageA11 and MageA6 are co-expressed in human prostate cancer samples.
|
28542476 |
2017 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression of MAGEA6 in GC tissues represents a promising biomarker for assessing the malignant phenotype of GC.
|
31704814 |
2019 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Although MAGE-6 and MAGE-12 were originally identified in malignant melanoma there are no studies reporting the frequency of expression of these antigens in this malignancy.
|
10890380 |
2000 |
|
melanoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion.
|
10064076 |
1999 |
|
melanoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma.
|
12631591 |
2003 |
|
melanoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Moreover, the CTLs also recognized a MAGE-6-positive melanoma line transfected with the B*3701 molecule.
|
10363990 |
1999 |
|
melanoma
|
0.040 |
Biomarker
|
disease |
LHGDN |
These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma.
|
12631591 |
2003 |
|
melanoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We have recently identified helper T cell epitopes derived from the MAGE-6 gene product; a tumor-associated antigen expressed by most melanomas and renal cell carcinomas.
|
12208877 |
2002 |
|
melanoma
|
0.040 |
Biomarker
|
disease |
LHGDN |
We have recently identified helper T cell epitopes derived from the MAGE-6 gene product; a tumor-associated antigen expressed by most melanomas and renal cell carcinomas.
|
12208877 |
2002 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The tumour samples expressed MAGE-12 (74%) and MAGE-6 (64%) mRNA at much higher frequencies than the other MAGE genes.
|
10890380 |
2000 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Cancer-germline genes were also implicated in the regulation of tumor metabolism (MAGEA3/MAGEA6).
|
28342986 |
2017 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The duplicated segments comprise highly similar genes, including MAGEA3 and MAGEA6, which display specific expression in testicular germline cells, and also become aberrantly activated in a variety of tumors.
|
31593956 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In vivo, MAGEA6 shRNA-bearing 786-O tumors grew significantly slower in nude mice than the control tumors.
|
29448247 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Although MAGE-6 and MAGE-12 were originally identified in malignant melanoma there are no studies reporting the frequency of expression of these antigens in this malignancy.
|
10890380 |
2000 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Database search confirmed that MageA11 and MageA6 are co-expressed in human prostate cancer samples.
|
28542476 |
2017 |
|
Renal Cell Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma.
|
12631591 |
2003 |